medacorp event updat immuno-oncolog washington dc
medic meet diabet technolog intern confer societi
medic innov technolog intern societi traumat stress studi
societi immunotherapi cancer adap imdz iph tril tsro
link planner vascular intervent advanc american associ studi
liver diseas
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
explor strateg option could help unlock valu
analysi discount rate termin growth rate
bottom line follow earn report zemdri sale vs expect
field forc reduct effect earli novemb personnel
temper forecast zemdri initi sale ramp although note initi indic
remain promis continu see sale potenti rang
off-set reduc oper cost announc today surpris hear
compani initi strateg review explor altern given compani need
cash tough initi launch ramp anti-infect space held view
consolid anti-infect space drive signific valu could potenti
spark consolid said continu believ zemdri offer uniqu
valuabl treatment option estim asset could worth multipl time
hand strateg buyer reiter op
zemdri sale miss expect initi indic look promis
compani implement restructur effort conserv cash
compani initi strateg review explor altern maxim sharehold valu
bottom line spoke manag ceo evp cfo svp strategi
ir modest ebitda miss driven slower ramp treatment growth due time de
novo elev employe health plan cost expect ramp de novo
slightli expect due delay receiv certif expect
low end guidanc rang activ address ramp hire consult firm
gain certif begin op revenu per treatment headwind cost
per treatment face headwind higher employe health plan cost margin improv bp qoq
adopt calcimimet improv expect normal esa
transit aranesp mircera manag host call edt expect color
fundament de novo clinic build recent polici pressur around charit premium
assist volum expect network
revenu ebitda less nci modest miss expect ramp treatment growth de
novo expect
non-acquir treatment volum growth normal basi slightli expect
ramp expect time de novo open
ebitda margin line bp qoq adopt calcimimet
cffo yoy even settlement though leverag year-
ebitda expect low end guidanc mm due lower treatment growth
expect vs estim consensu mm
manag host confer call friday novemb et dial-in detail domest
recap pipelin track present
dcf analysi revenu multipl dr tgr
bottom line asln report financi result morn provid pipelin updat
in-lin expect asln oncology-focus biopharmaceut compani base
singapor develop therapeut global market compani lead program varlitinib
revers small molecul pan-human epiderm growth factor receptor pan-her inhibitor
target recal varlitinib origin licens arri nr
complet five phase studi rang solid tumor asln develop varlitinib indic
high preval asia includ biliari tract cancer gastric cancer varlitinib clinic
data gener date asln arri demonstr activ want see
clinic mechanist valid varlitinib given biliari tract cancer histor difficult
space drug develop mechanist advantag varlitinib pan-her inhibitor
remain unclear given implic target remain poorli understood overal
posit asln asia focus develop strategi experi manag team
want see clinic mechanist valid varlitinib catalyst-rich reiter
multipl data readout remain
asln end cash equival
doptelet still launch slowli profit pt
 methodolog dcf discount rate termin valu
bottom line lower price target dova reiter market
perform rate stock outlook slower uptak doptelet initi indic
chronic liver diseas cld higher commerci expens potenti launch doptelet
immun thrombocytopen purpura itp dova report last night doptelet drug
sold includ approxim increment channel inventori quarter
vs growth underli demand appear slower expect
obviou catalyst inflect near term meantim initi gross-to-net spread
doptelet higher drug launch dova expect remain
least next coupl quarter given softer revenu outlook doptelet near
term higher potenti expens launch itp remain cautiou stock maintain
neutral rate lower price target
doptelet launch trajectori slower expect
gross-to-net like remain high anoth coupl quarter
lower near-term revenu forecast higher sg pt
revenu mm ep present quarterli ep may sum annual total due chang
busi continu perform cch move regulatori stage
ev/ebitda multipl
bottom line believ neg stock reaction vs tuesday last two
day despit strong cch data beat rais quarter overdon believ
driven reposit follow nice recent run stock well concern
around robust clinic data cch disagre remain posit
stock higher margin busi xiaflex steril inject continu outperform
us gener busi continu see greater stabil believ question around
regulatori pathway commerci strategi cch cellulit valid believ clinic
data strong hear anyth week would suggest endo increment
wors abil capit opportun see current stock weak buy
opportun reiter op rate pt
chang model
manag reiter strength cch phase data move regulatori discuss
fda
continu cautiou optim us gener
manag continu opportunist busi develop
steril inject continu key growth pillar
shift time somerset deal closur
manag continu classifi discuss potenti settlement opioid construct
bodi note
look breakthrough year major event roxa pamrevlumab
bottom line yesterday report oper result provid updat
progress clinic program roxadustat pamrevlumab indic
initi phase studi pamrevlumab idiopath pulmonari fibrosi ipf
studi enrol subject placebo control fashion timelin key phase
disclosur roxadustat re-affirmed quarter compani indic pool
major advers cardiac event mace safeti analysi expect march-april time frame
mostli consist expect although size like durat ipf trial
consider smaller thu shorter expect result acceler
time pamrevlumab expect launch model late modest posit effect
price target increas continu see particularli well
posit term major pivot trial regulatori mileston reiter outperform
rate stock
yesterday disclos key detail pamrevlumab phase program ipf better
previous expect
confirm prior guidanc top-lin efficaci data us/eu roxadustat phase trial
prior end year
updat price target base earlier pamrevlumab launch
revenu ep present
bottom line reiter op given acceler core us spine result
higher rev/ep outlook increas confid compani sustain
double-digit revenu growth trajectori beyond time sustain
industri lead ebitda margin dd profit growth two new product cycl
robot trauma earli stage think capabl gener double-digit
top-lin compound-annual-growth-rate upsid potenti even above-consensu out-yr forecast
may constern gmed weaker-than-expect robot placement management
attribut season impact nass custom wait see launch
industri would urg investor consid follow revenue guidanc increas
higher indic revenue vs consensu street alreadi model sequenti higher
robot unit management note call placement month oct alon match entir
us robot placement figur estimate math need
place robot nov-dec season strongest capit month year achiev
estim improv underli trend us core spine acceler
off-set capit season implant pull-through start preliminari effect
pick momentum meanwhil trauma revenue contribut still entir
front pt goe roll forward valuat ebitda assum current
multipl hold
sale consensu driven us spine ep gm expans lower tax
meaning us spine acceler -- -some robot implant pull-through alreadi start
robot perform light season weaker capit qtr
new excelsiu indications/function
revenu million
fda final feedback nolasiban delay invest thesi intact
outperform market cap price price target methodolog dcf
cash flow use wacc
bottom line earn line compani report ep vs lp estim
consensu updat model quarterli result make chang
estim go forward continu see favor risk/reward profil ahead phase
readout nolasiban ivf linzagolix uterin fibroid asset believ
best-in-class larg high unmet need market acknowledg delay fda
feedback nolasiban clinic program us approv add near-term uncertainti
remain optimist potenti eu larger us market reiter op
pt
fda feedback nolasiban inconclus manag hope get clariti earli
phase studi nolasiban ivf implant expect initi
linzagolix uterin fibroid two ph progress track data readout
ph program linzagolix endometriosi initi
pre-term labor initi proof concept data
obseva cash cash equival
bodi note includ market model linzagolix page nolasiban page
also includ latest compani model start page
solid quarter adopt momentum ramp
bottom line report sale y/i vs us street
addit deliv sequenti top-lin growth vs solid
encouragingli earli feedback commerci posit patient
order system/backlog record sale quarter manag
reiter sale guidanc roll-out contribut sale
impli q/q growth reflect strong adopt momentum
 importantli believ launch good start mobil clinic
-- host physician date -- abl address train issu get
clinician comfort insert explant view compani plan add addit
sale rep exit rep vs today believ biggest barrier
adopt reimburs alreadi secur coverag aetna gave
access cover live also bode well on-going convers payer
remain op increas confid verg dramat sale
inflect point beyond on-going launch eversens implant
continu glucos monitor cgm believ nearli total address market
 alon believ eversens play uniqu role cgm marketplac
grow marketplac appeal patient -- like type initi -- never
would consid cgm previous due burden therapi cgm still
penetr type patient signific runway faster market growth
revenu mm
view fintepla commerci path track w/ label gain
bottom line report manag drug compani paint pictur team
method work secur regulatori approv lead product simultan prepar
potenti commerci nda fda roll review investig drug fintepla underway
inform previous agreed-on submiss plan recent pre-nda meet fda yield
opportun improv fintepla us label step toward european market approv
fintepla dravet continu develop fintepla lennox-gastaut syndrom lg
track addit site europ japan sought half-billion dollar bank
compani level financi flexibl ampl near-term goal
nda fda roll review fintepla underway inform previous agreed-on submiss plan
among agenc compani
recent pre-nda meet fda yield opportun improv fintepla us label addit
analys exist clinic data seen
step toward european market approv fintepla dravet continu
develop fintepla lg track clinic studi site open site expect
europ japan
recent capit rais compani level financi flexibl look ampl
team execut well toward key product regulatori approv potenti commerci launch
bottom line call cfo jorg gomez disclos compani expect oper profit
dollar flat q/q come away quarter call somewhat concern
guid may risk flat q/q oper profit growth impli us ramp
may overli optimist given heighten scrutini brand price increas primarili
occur januari howev also encourag hear manag cost save
initi progress well compani may track initi estim
annual save model remain review
bottom line deciphera provid corpor updat conjunct financi result
compani disclos chief medic offic oliv rosen leav pursu
opportun although deciphera clinic program gastrointestin stromal tumor gist
appear advanc line expect manag turnov appear
pressur share morn manag commentari departur stress lack
fundament read-through clinic program belief disrupt
minim deciphera begin search identifi perman replac
compani view opportun better align compani transit near
commerci organ compani also pursu develop addit
tumor type beyond gist includ expand cohort lung cancer melanoma solid
ep
bottom line outlook basic expect much
chang view stock reiter mp rate encourag organ growth
improv slightli sell day adj guidanc impli step-
pro-forma basi still remain lsd rang see ton rev/
ep upsid lever tap remain mp-rate pend greater confid ep upsid potenti
 cyno number begin move need come and/or organ
cc revenue growth sustain move back msd territori faster expect price target
unchang believ stock trade multipl ep
recap pipelin track sadal result
bottom line report financi result provid pipelin updat larg in-
line expect key updat announc yesterday selinexor receiv fast track
design treatment patient relaps refractori r/r diffus larg b-cell lymphoma
dlbcl recal american societi hematolog abstract provid littl new
data confirm data phase iib sadal studi evalu selinexor r/r dlbcl would
present abstract overal view selinexor activ drug could
place dlbcl treatment landscap recent conduct deep dive medacorp
key opinion leader kol address multipl controversi ahead top-lin readout sadal
kol address controversi ahead registr dlbcl data addit continu
prepar potenti commerci launch selinexor penta-refractori multipl myeloma pdufa
date base posit result storm studi remain posit expect
approv selinexor penta-refractori multipl myeloma base kol check kol address
controversi ahead storm data reiter op
revenu mm
oper progress continu wait laro approv
bottom line loxo report financi result in-lin oper updat key
near term focu compani expect approv larotrectinib trk driven tumor
fda decis expect pdufa date key fundament driver
loxo share view regulatori approv larotrectinib signific valid event
compani loxo expect present pivot data ahead late nda
file compani next clinic candid btk inhibitor begin enrol patient
maintain op
recap favor safeti orion bode pivot data
discount rate termin growth
bottom line orion studi orion cardiovascular outcom trial cvot
way pend posit outcom once-every-six month dose inclisiran
hypercholesterolemia may offer differenti complianc profil pt either intoler
inadequ respond statin therapi reiter op maintain pt mdco
ep estim
replac codi phipp ceo
bottom line overli surpris see owen minor announc morn
replac ceo codi phipp sinc report disappoint result
trade includ initi sell-off codi phipp three year
ceo posit trade phipp knowledg level industri seem
good given consult background result consist disappoint
continu face signific headwind varieti front
top-lin miss guidanc lower due rx
bottom line report ep beat vs lp vs consensu
howev top line continu weak guidanc lower primarili
due rx segment complet surpris given prescript trend
expect lower guidanc put pressur stock today total revenu miss lp estim
consensu main underperform rx segment vs con
oper margin larg came line ep beat due lower tax rate vs
lp manag lower total compani sale guidanc adjust
ep primarili due lower expect rx along lower margin
expect chca partial off-set higher margin expect chci new guid impli
sale vs con ep midpoint vs con
everyth goe wright momentum shld carri pt
sale
bottom line deliv solid beat rais expect estim upwardli revis
toward above-consensu forecast reflect improv underli
busi trend well addit cartiva uniqu asset lower extrem
biolog franchis re-acceler growth us upper extrem share gain continu think
well posit head continu believ end-market remain healthi
grow per management well posit take share within
sustain dd low-teen better growth pt goe pt vs prior roll-forward
valuat appli group forward multipl ev/sal revenue
rev/ep continu oper ex-larg joint move disc op ep ex-amort item
recap steadi progress maintain expect decemb
outperform market cap price price target methodolog dcf
new guid achiev visibl ebitda need
the-part weight average ev/ebitda multipl
unev continu like tenapanor potenti
analysi discount rate termin valu
recap hand on-deck promis asset preclin data
improv underli trend outweigh macro item pressur
ep
updat execut continu zanubrutinib time slip trim pt
 day takeaway strong foundat gene tx pivot ach data
of-the-part dcf discount rate pipelin termin growth rate
recap pipelin track initi arginas data
deal pois close pbm sell season robust pt
guid rais cinvanti strength visibl adcom
outperform market cap price price target methodolog dcf
cash flow use wacc
star align rais ep pt cfo
 methodolog price-to-earnings ep
data pool top-lin report phase studi
recap sophia enrol complet
blend discount sale multipl analysi dcf w/ discount rate termin growth rate
recap clinic program advanc includ partnership
analysi discount rate termin growth rate
recap await initi triplet data high dose doublet data
use discount rate termin growth rate
discount rate termin gr rate
expect still like lead asset upsid
analysi discount rate termin valu
probability-weight dcf analysi discount rate termin growth rate
biopharma titl highlight i/o progress emerg mechan action
novemb tsro comin phase data nsclc
anticip present tsro dose expans data amber
trial studi combin refractori non-
follow esmo io combin failur investor becom increasingli
skeptic assign valu product demonstr efficaci single-arm combin
regimen difficult discern increment benefit investig agent
backbon
tsro point clinic bar docetaxel set believ
investor like want see least increment efficaci alon
result respons rate bar combin
addit overal respons rate tsro believ dose respons seen
data escal kept constant provid confid
contribut result
data note includ first monotherapi data antibodi
updat data phase garnet trial r/r nsclc
cautious optimist go given high level investor skeptic
among multipl present phase solid tumor studi enoblituzumab
like greatest interest investor
enoblituzumab current evalu phase combin studi keytruda
patient melanoma non-smal cell lung cancer nsclc head neck
cancer scchn urotheli cancer
believ investor expect enoblituzumab low manag guid
provid clariti futur develop step near-term
also like interest investor interim phase solid tumor data
partner mp nov
view emerg immuno-oncolog pipelin highlight franchis
signific sourc upsid stock
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
given superl clinic data present date expect fda approv
nov link note
larotrectinib loxo lead agent potent specif pan-trk tropomyosin receptor
kinas inhibitor combat basket tumor includ lung breast colon
trk biomark individu estim us
larotrectinib next-gen trk inhibitor partner bayer hold
ex-u commerci right pay loxo tier double-digit royalti ex-u sale
loxo bayer co-develop us cost profit split loxo
receiv up-front payment potenti receiv mileston payment
us ou larotrectinib
project combin larotrectinib peak probability-of-success
adjust sale us europ larotrectinib eu
submit august
dec epo patent challeng relat rubraca ovarian prostat
dec european patent offic epo hear oral argument render
opinion patent challeng camsyl salt patent provid ip protect
eu drug rubraca
challeng file divis sandoz anonym parti contend
epo patent recent grant clovi novel -- argument preliminari
opinion agre cite prior art exist applic file
medacorp specialist review preliminari opinion render april felt
opposit strong argument could result narrow patent claim
claim narrow eu could make invent step difficult
uphold unexpect product attribut may compar broadli potenti
open door prior art consid
view eu patent challeng relev impact potenti
takeout option potenti read-through us exclus
composit matter patent expir without addit patent support drug
intellectu properti ip runway relev us patent howev like
hotli debat even dec goe poorli
genesight guid studi public remov one journal submit
anoth effort protect genesight algorithm
believ ultim delay technic assess commerci payor make
coverag decis well investor look sign potenti upsid busi
compani expect receiv coverag decis public genesight
pharmacogenom test genesight account compani revenu
remain singl signific driver upsid obtain broad reimburs
commerci payor
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data present american psychiatr associ
confer may provid sub-analysi patient fail
chang view medacorp specialist payer physician
link takeaway meet manag thought
sourc leerink research compani inform factset price prior day
pdufa revefenacin lama copd link link recent note
fda adcom joint anesthet analges drug product drug safeti
pdufa roxicodon abuse-deterr formul immediate-releas single-
fda adcom scienc advisori board circulatori system devic
fda adcom joint anesthet analges drug product drug safeti
north carolina dhh award rfp transit medicaid program manag
may texa hhsc award rfp star plu medicaid manag care program
societi immunotherapi cancer adap imdz iph tril
tsro link planner
intern confer societi medic innov technolog
intern societi traumat stress studi
american associ studi liver diseas zfgn
american societi cytopatholog
american heart associ link preview impella stemi
societi neuro-oncolog
american colleg allergi asthma immunolog
intern societi pediatr oncolog
radiolog societi north america
life scienc biolog engin confer
societi urolog oncolog
intern feder adipos therapeut scienc
asian pacif societi respirolog
american societi hematolog present pst
sadal studi abstract session
abstract paraxysm nocturn hemoglobinuria
american societi health-system pharmacist
intern symposium als/mnd
american societi cell biolog
american colleg neuropsychopharmacolog
manag end sell season
univers coverag
calendar event
model model loxo
mdco recent updat pleas contact leerink
repres wish review
biopharma preview gener pain women health anti-infect
 biotech earn unlik offer much excit best
hcit distribut preview price pressur continu gener
medic suppli devic individu co preview cardio large-cap diversifi
medic suppli devic individu co preview ortho supplies/cap equipment/
payor servic posit catalyst
arql -- flash increment new data disclos abstract present
impress beta-th
-- flash abstract show strong symptom relief advanc sm import
imdz -- flash minor updat abstract market perform
-- flash abstract encourag investor focu remain forward-i
-- flash multipl present full sadal data confer outperform
-- flash data abstract still earli present
-- flash abstract highlight earli efficaci present
 disappoint ctad fade prospect ban bace market
-- flash data thin unconvinc benefit limit carrier
 ctad disclosur unlik bolster amyloid outlook market perform
